Citius Pharmaceuticals Inc (CTXR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Citius Pharmaceuticals Inc (CTXR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8163
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Citius Pharmaceuticals Inc (Citius), formerly Trail One Inc is a specialty pharmaceutical company that focuses on the development and commercialization of anti-infective products in adjunct cancer care, and critical care drug products. The company’s proprietary product candidates include Mino-Lok, an antibiotic lock solution intended for the treatment of patients with catheter-related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine intended to provide anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. Citius is headquartered in Cranford, New Jersey, the US.

Citius Pharmaceuticals Inc (CTXR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Leonard-Meron Biosciences Raises USD0.6 Million in Venture Financing 12
Licensing Agreements 13
Leonard Meron Biosciences Expands Licensing Agreement with Novel Anti-Infective Therapeutics 13
Leonard-Meron Biosciences Amends Licensing Agreement with Novel Anti-Infective Therapeutics 14
Equity Offering 15
Citius Pharma Raises USD10 Million in Public Offering of Shares and Warrants 15
Citius Pharma Plans to Raise USD5.6 Million in Public Offering of Shares 17
Citius Pharma to Raise USD2 Million in Private Placement of Shares 18
Citius Pharma Plans to Raise Funds through Public Offering of Shares 19
Citius Pharma to Raise USD6 Million in Private Placement of Shares 20
Citius Pharma Plans to Raise up to USD50 Million in Public Offering of Shares and Warrants 21
Citius Pharma Raises USD6.8 Million in Public Offering of Shares and Warrants 22
Citius Pharma Raises USD0.8 Million in Third Tranche of Private Placement of Units 24
Citius Pharma Raises USD0.2 Million in Seconds Tranche of Private Placement of Units 25
Citius Pharma Plans to Raise Funds in Public Offering of Shares 26
Citius Pharma Raises USD0.4 Million in Private Placement of Units 27
Citius Pharma Raises USD4.6 Million in Private Placement of Units 28
Citius Pharma Raises USD3 Million in Private Placement of Shares 29
Citius Pharma Raises USD1.5 Million in Private Placement of Units 30
Citius Pharma Raises USD0.1 Million in Private Placement of Units 31
Citius Pharma Raises USD2.04 Million in Private Placement of Shares 32
Acquisition 33
Citius Pharma Acquires Leonard Meron Biosciences 33
Trail One Acquires Citius Pharma in Reverse Takeover Transaction 34
Citius Pharmaceuticals Inc – Key Competitors 35
Citius Pharmaceuticals Inc – Key Employees 36
Citius Pharmaceuticals Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Product News 38
02/13/2018: Citius Publishes Expert Roundtable Discussion On Treatment Considerations For Catheter Related Bacteremias 38
Clinical Trials 39
Mar 06, 2018: Citius Reports Progress in Hemorroid Treatment Program 39
Feb 15, 2018: Citius Announces Enrollment Of First Patient In The Mino-Lok Phase 3 Trial 40
Dec 06, 2017: Mino-Lok Phase 3 Clinical Trial Supplies Shipped to Sites 41
Nov 07, 2017: International Study at MD Anderson Sister Institutions Supports Mino Lok Phase 2b Results: Poster Presented at ID Week 42
Oct 31, 2017: Citius Pharmaceuticals Receives “Fast Track” Designation By FDA For Mino-Lok Investigational Trial 43
Sep 05, 2017: Citius Pharmaceuticals Provides Phase 3 Update On Mino-Lok Clinical Trial Following FDA Meeting 44
Jan 11, 2017: Citius Mino-Lok Addresses Resistant Pathogens 45
Other Significant Developments 46
Oct 11, 2017: Citius Pharmaceuticals Issues Shareholder Letter 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Citius Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Leonard-Meron Biosciences Raises USD0.6 Million in Venture Financing 12
Leonard Meron Biosciences Expands Licensing Agreement with Novel Anti-Infective Therapeutics 13
Leonard-Meron Biosciences Amends Licensing Agreement with Novel Anti-Infective Therapeutics 14
Citius Pharma Raises USD10 Million in Public Offering of Shares and Warrants 15
Citius Pharma Plans to Raise USD5.6 Million in Public Offering of Shares 17
Citius Pharma to Raise USD2 Million in Private Placement of Shares 18
Citius Pharma Plans to Raise Funds through Public Offering of Shares 19
Citius Pharma to Raise USD6 Million in Private Placement of Shares 20
Citius Pharma Plans to Raise up to USD50 Million in Public Offering of Shares and Warrants 21
Citius Pharma Raises USD6.8 Million in Public Offering of Shares and Warrants 22
Citius Pharma Raises USD0.8 Million in Third Tranche of Private Placement of Units 24
Citius Pharma Raises USD0.2 Million in Seconds Tranche of Private Placement of Units 25
Citius Pharma Plans to Raise Funds in Public Offering of Shares 26
Citius Pharma Raises USD0.4 Million in Private Placement of Units 27
Citius Pharma Raises USD4.6 Million in Private Placement of Units 28
Citius Pharma Raises USD3 Million in Private Placement of Shares 29
Citius Pharma Raises USD1.5 Million in Private Placement of Units 30
Citius Pharma Raises USD0.1 Million in Private Placement of Units 31
Citius Pharma Raises USD2.04 Million in Private Placement of Shares 32
Citius Pharma Acquires Leonard Meron Biosciences 33
Trail One Acquires Citius Pharma in Reverse Takeover Transaction 34
Citius Pharmaceuticals Inc, Key Competitors 35
Citius Pharmaceuticals Inc, Key Employees 36
Citius Pharmaceuticals Inc, Subsidiaries 37

List of Figures
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Citius Pharmaceuticals Inc (CTXR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Petron Corp (PCOR):企業の財務・戦略的SWOT分析
    Petron Corp (PCOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Skyworks Solutions Inc (SWKS):企業の財務・戦略的SWOT分析
    Skyworks Solutions Inc (SWKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Aruba Networks, Inc.:企業の戦略・SWOT・財務情報
    Aruba Networks, Inc. - Strategy, SWOT and Corporate Finance Report Summary Aruba Networks, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Islet Sciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Islet Sciences Inc (Islet Sciences) is a drug development company that develops medicines and technologies for the treatment of metabolic diseases. The company's pipeline products include immune modulating small molecule interleukin 12 inhibitors to address disorders associated with inflamma …
  • Abbott Diabetes Care Inc:医療機器:M&Aディール及び事業提携情報
    Summary Abbott Diabetes Care Inc (ADC), formerly TheraSense Inc, a subsidiary of Abbott Laboratories, is a medical device company that discovers, develops, manufactures, and markets pharmaceuticals and medical products for personal use and hospital use. The company’s products include glucose monitor …
  • Probi AB (PROB):製薬・医療:M&Aディール及び事業提携情報
    Summary Probi AB (Probi) is a biotechnology company develops, produces and markets probiotics. The company offers licenses for its technology and sells finished products in bulk. It focuses on products for the improvement of gastrointestinal health and immune system. It distributes its products to l …
  • Samart Corporation Plc (SAMART):企業の財務・戦略的SWOT分析
    Samart Corporation Plc (SAMART) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Laboratoires Pierre Fabre SA:企業の戦略的SWOT分析
    Laboratoires Pierre Fabre SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Nanomerics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Nanomerics Ltd (Nanomerics) is a healthcare solution provider that develops drug delivery solutions for poorly water soluble drugs, nucleic acids and peptides. The company offers products such as METDoloron, METSporine, METAmphizon, METEnkalon, MET undisclosed, MET ocular undiscl, ocular und …
  • Cell Therapy Catapult Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Cell Therapy Catapult Ltd (Catapult) is a provider of cell and gene therapy life cycle solutions. The company offers services such as industrialization, manufacturing, regulatory, health economics and market access, non-clinical safety and clinical operations. Its health economics and market …
  • Oncgnostics GmbH-医療機器分野:企業M&A・提携分析
    Summary Oncgnostics GmbH (Oncgnostics) is an in-vitro diagnostic company that specializes in the development of in-vitro diagnostic tests for the therapeutics area of cancer. The company’s pipeline offers GynTect technology, a system based on the detection of epigenetic biomarkers, mainly in the met …
  • The Scripps Research Institute-医療機器分野:企業M&A・提携分析
    Summary The Scripps Research Institute (TSRI) is a research and educational organization that conducts research in the areas of neurosciences, cardiovascular diseases, immunology, autoimmune diseases, chemistry, molecular and cellular biology, virology and synthetic vaccine development. The institut …
  • Cooper-Standard Holdings Inc.:企業の戦略・SWOT・財務情報
    Cooper-Standard Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Cooper-Standard Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Smith & Williamson Holdings Ltd:企業の戦略的SWOT分析
    Smith & Williamson Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Television Francaise 1 SA:企業の戦略・SWOT・財務分析
    Television Francaise 1 SA - Strategy, SWOT and Corporate Finance Report Summary Television Francaise 1 SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • ORBIT Communication Systems Ltd:企業の戦略・SWOT・財務分析
    ORBIT Communication Systems Ltd - Strategy, SWOT and Corporate Finance Report Summary ORBIT Communication Systems Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Acorn Energy Inc (ACFN):石油・ガス:M&Aディール及び事業提携情報
    Summary Acorn Energy Inc (Acorn) is an energy technology holding company which operates electricity delivery, emergency back-up power generation, and remote monitoring and control systems through its subsidiaries. The company develops and produces sonar systems for the defense, HLS, energy and comme …
  • Vaxart Inc (VXRT):企業の財務・戦略的SWOT分析
    Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Arsenal Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Arsenal Medical Inc (Arsenal) is a platform technology company that develops novel therapeutic polymer based foams. The company’s products include in-situ forming materials, in-situ forming polymeric foam and in-situ curing elastomeric polymer material. It offers in-situ forming materials to …
  • AngioDynamics Inc (ANGO):医療機器:M&Aディール及び事業提携情報
    Summary AngioDynamics Inc (AngioDynamics) is a provider of minimally invasive medical, surgical and diagnostic devices. Its product portfolio encompasses peripheral vascular products, radiofrequency ablation and NanoKnife systems, vascular access products, angiographic products and accessories, prod …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆